Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

This study looks at the possible benefits of screening people using a new
Zio Patch monitor to detect atrial fibrillation.

Atrial fibrillation is an irregular heart rhythm which may also be faster than normal. While some people with atrial fibrillation have symptoms such as palpitations, light-headedness or shortness of breath, others have no symptoms. The irregular heart beat may also be intermittent.

Small clots can form in the heart due to the irregular heart beat, these clots may travel to the brain where they can cause a stroke. People with atrial fibrillation are thought to be around five times more likely to have a stroke. 

Atrial fibrillation is normally diagnosed using an electrocardiogram (ECG) which records the heart rate at a single point in time. However, as atrial fibrillation may only happen intermittently an ECG might not always detect atrial fibrillation. Also, people without symptoms of atrial fibrillation are unlikely to see their doctor to have their pulse checked and have an ECG done.

A Zio Patch monitor gives a continuous heart trace reading for two weeks and the AMALFI study investigates whether wearing a Zio Patch will increase the number of people detected with atrial fibrillation.

Half of the study participants will wear the patch and half will not, so we can compare the Zio Patch to the usual NHS medical care. The Zio Patch results will be sent to GPs who will discuss any changes in treatment that might be needed. The study team will continue to monitor each participant's medical record for five years.

We hope that this will allow more people to be given the right treatment at an earlier stage and so bring down their risk of having a stroke.

Our team

  • Louise Bowman
    Louise Bowman

    Professor of Medicine & Clinical Trials, and Honorary Consultant Physician (Lipidology)

  • Richard Bulbulia
    Richard Bulbulia

    Research Fellow, Clinical Trial Service Unit, University of Oxford

Related research themes